SYSPHARMAD

A systems pharmacology approach to the discovery of novel therapeutics in Alzheimer´s disease

Coordinatore	FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Spain [ES]
Totale costo	1˙296˙000 €
EC contributo	1˙296˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-CoG
Funding Scheme	ERC-CG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-04-01   -   2019-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)  Organization address address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA city: BARCELONA postcode: 8028 contact info Titolo: Dr. Nome: Patricio Cognome: Aloy Calaf Email: send email Telefono: 34934039690 Fax: 34934039954	ES (BARCELONA)	hostInstitution	1˙296˙000.00
2	FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)  Organization address address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA city: BARCELONA postcode: 8028 contact info Titolo: Ms. Nome: Sònia Cognome: Saborit Sanz Email: send email Telefono: 34934031101 Fax: 34934037114	ES (BARCELONA)	hostInstitution	1˙296˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Alzheimer´s disease (AD) is the most common form of dementia, with over 35 million people suffering from it worldwide, and it constitutes a personal and societal tragedy of immense proportions. Fifty years of intense research have revealed many key elements of the biology of this neurodegenerative disorder. However, our understanding of the molecular bases of the disease is still very limited, and the available medical treatments for AD are purely symptomatic and hardly effective. It is now clear that the modulation of a single target is unlikely to yield the desired outcome, and we should move from gene-centric to network-centric therapeutic strategies. In addition, we should focus on early (asymptomatic) phases of AD, before the brain damage is irreversible, and the identification of molecular biomarkers to monitor the response of patients is paramount.

Accordingly, the main objective of our proposal is the identification of novel biomarkers in AD to monitor the onset and progression of the pathology from very early stages, and to discover combinations of drug targets and chemical compounds able to modify the biology of the disease. We will first run proteomics and transcriptomics experiments, in AD mouse models, to reveal the organization of proteins and genes that are up- or down-regulated at different ages and AD stages, and their potential translocation into/out of mitochondria. We will then construct the AD-associated network, incorporating clinical data, which we will use as a framework for the integration and analyses of the –omics data collected. We will transform the static data snapshots, corresponding to the different AD stages, into a dynamic model able to explain the progression of the disease, providing hints as to the best strategies to monitor and modulate AD evolution. We will finally design and validate a systems pharmacology strategy, based on concerted multi-target perturbations with small molecules, to modify the biology of the disease.'